QuintilesIMS leading Big Pharma firms in oncology collaboration

By Melissa Fassbender contact

- Last updated on GMT

According to WHO, cancer is a leading cause of death and morbidity in Europe with more than 1.7 million deaths and three million new cases each year. (Image: iStock/Toa55)
According to WHO, cancer is a leading cause of death and morbidity in Europe with more than 1.7 million deaths and three million new cases each year. (Image: iStock/Toa55)

Related tags: Medicine

The new collaborative initiative will be led by QuintilesIMS, with founding partners including Bristol-Myers Squibb, Eli Lilly and Company, Merck KGaA, and Pfizer.

According to the contract research organization (CRO), there is currently a lack of information and inconsistencies in knowledge surrounding the “real-world use” of oncology products in Europe.

The new collaboration seeks to address this issue and to ultimately provide a clearer picture of how anti-cancer treatment are used in the everyday.

"Oncology is a major human and economic burden for European healthcare systems,​" Sally Beatty, a company spokesperson from Pfizer, told Outsourcing-Pharma.com.

"We believe that the data gaps are complex and the topic is so important that a collective approach, encompassing the expertise of range of industry leaders, will allow for a more robust, comprehensive and complete evidence-based resource that will benefit the EU healthcare systems and, ultimately, patients​."

Specifically, the companies will look into how oncology products are used by patient type, and with what sequences and combinations of therapies, and in which indications.

QuintileIMS explained that the initiative is “intended to provide more timely, consistent and comprehensive data resources that could be used to provide further insight for healthcare systems to make better informed decisions on patient care in the future.”

Earlier this week QuintilesIMS also reported that is has has agreed to purchase TKL​ Research’s Clinical Trials Division (CTD), which will become a part of Novella Clinical, a Quintiles company.

Both announcements follow Quintiles' completed merger​ with IMS Health, which became official last month.

The merger was initially announced​ in May of this year, with new senior management roles announced​ in late August. 

Related topics: Clinical Development, Pfizer, Eli Lilly

Related news

Show more

Follow us

Featured Events

View more

Products

View more

Webinars